Hepatitis virus-like particles as potential cancer treatment

UC Davis researchers have developed a way to use the empty shell of a Hepatitis E virus to carry vaccines or drugs into the body. The technique has been tested in rodents as a way to target breast cancer, and is available for commercial licensing through UC Davis Office of Research.

Hepatitis E virus is feco-orally transmitted, so it can survive passing through the digestive system, said Marie Stark, a graduate student working with Professor Holland Cheng in the UC Davis Department of Molecular and Cell Biology.

Cheng, Stark and colleagues prepared virus-like particles based on Hepatitis E proteins. The particles do not contain any virus DNA, so they can’t multiply and spread and cause infections.

Hepatitis E virus-like particles can be modified so that molecules such as LXY30, which binds to cancer cells, can be attached to them. (Marie Stark/UC Davis)

Hepatitis E virus-like particles can be modified so that molecules such as LXY30, which binds to cancer cells, can be attached to them. (Marie Stark/UC Davis)

Such particles could be used as vaccines that are delivered through food or drink. The idea is that you would drink the vaccine, and after passing through the stomach the virus-like particles would get absorbed in the intestine and deliver vaccines to the body.

But the particles could also be used to attack cancer. Stark and Cheng did some tinkering with the proteins, so that they carry sticky cysteine amino acids on the outside. They could then chemically link other molecules to these cysteine groups.

They worked with a molecule called LXY-30, developed by researchers at the UC Davis Comprehensive Cancer Center, which is known to stick to breast cancer cells. By using a fluorescent marker, they could show that virus-like particles carrying LXY-30 could home in on breast cancer cells both in a laboratory dish and in a mouse model of breast cancer.

Results of the study are published in the journal Nanomedicine. Information about licensing the technology can be found here.

So perhaps one day, cancer patients might drink their medicine and UC Davis-designed virus-like particles carrying anticancer drugs will home in on their target.

More information

Description of Hepatitis E virus-like particles

4 responses to “Hepatitis virus-like particles as potential cancer treatment

  1. Our group is about to start working with a Zika protein antigen and using your VLP expression technology would be a perfect way to raise antibodies against this antigen. It will also be a great project for your VLP technology and if successful will bring positive attention to your platform due to high publicity surrounding Zika.


    The target protein is as below:
    The Goal: VLP form in mammalian cells, preferably HEK 293 cells, in the amount of first 1mg, then additional 4mg [optional] or 6.5mg [optional]. You can add a HIS-tag for VLP detection, if necessary.
    The target: the prM envelope protein of Zika virus

    The Zika virus is a positive sense single-stranded RNA molecule 10794 bases long with two non-coding regions flanking regions known as the 5′ NCR and the 3′ NCR. The open reading frame of the Zika virus reads as follows: 5′-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3′ and codes for a polyprotein that is subsequently cleaved into capsid (C), precursor membrane (prM), envelope (E), and non-structural proteins (NS). The E protein composes the majority of the virion surface and is involved with aspects of replication such as host cell binding and membrane fusion. NS1, NS3, and NS5 are large, highly-conserved proteins while the NS2A, NS2B, NS4A, and NS4B proteins are smaller, hydrophobic proteins. Located in the 3′ NCR are 428 nucleotides that may play a part in translation, RNA packaging, cyclization, genome stabilization, and recognition. The 3′ NCR forms a loop structure and the 5′ NCR allows translation via a methylated nucleotide cap or a genome-linked protein.

    I would like to know whether you have any suggestions of expressing the Zika antigen in your VLPs for immunization.

    Thank you for your help and look forward to your reply.

Leave a Reply

Your email address will not be published. Required fields are marked *